The first year of a baby’s life is filled with milestones, but between sitting and standing up, holding his bottle, and playing peek-a-boo, there was one thing Landon Cato developed that his parents never anticipated: cancer. Landon was just shy of eight months old in July 2016 when his parents took him to the pediatrician, … Read more
From new immunotherapy treatments to improved understanding of the genetic mechanisms of pediatric tumors, the past year has brought many important advances against childhood cancers. We sat down with Scott Armstrong, MD, PhD, chair of Pediatric Oncology at Dana-Farber Cancer Institute, to discuss some of these developments. CAR T-Cell Therapy for Relapsed ALL A CAR … Read more
Pediatric oncologist Kimberly Stegmaier, MD, draws on Dana-Farber’s network of experts to work together on new treatment options for children with cancer.
In the context of a diagnosis of cancer, anemia can be caused by the cancer itself, chemotherapy treatments, or both.
Eli Morse has had to make major changes to his active lifestyle, but one thing has stayed the same: Eli and his family will continue to fight his aplastic anemia together.
With the advent of better treatments, more young patients treated for childhood cancers are surviving longer, and many reach the age when they consider starting families.
The differences between cancers in adults and children go well beyond age. In many respects, they are markedly different diseases.
Cameron Smith has spent decades traveling the country on his motorcycle, but nothing quite matches the car ride he took to Dana-Farber Cancer Institute this summer—his first visit in 40 years to the cancer center where Institute founder Sidney Farber, MD, saved his life in 1961.
Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center are leading a number of studies in osteosarcoma, a type of cancer that starts in the bones.
New technologies are being used to analyze exactly how DIPG develops in the first place.
An interventional radiology procedure stabilized the growth of a toddler’s rare liver tumor until he was able to receive a life-saving liver transplant. Today, he is healthy and thriving.
In 2009, Drew was diagnosed with aplastic anemia, a rare blood disorder. Because of a stem cell transplant, he was cured—and now, he has his mind set on becoming a pediatric oncologist.
Findings from clinical trials have increased survival rates significantly in the last several decades for children with germ cell tumors.
Pediatric leukemia patient Emma Duffin is in remission, thanks to the stem cell transplant made possible by her brother, Alexander.
Recent headways in pediatric liver tumor treatment include more targeted therapies that aim to hone in on the cancer and destroy it — while reducing the toxic effects of treatment on the body, when possible.
Boston-based researchers hope to optimize CAR T-cell therapies to target DIPG, aggressive and difficult-to-treat brain tumors, and other tough-to-treat cancers.
Leukemia, which usually occurs because of a mutation — or DNA change — is the most common childhood cancer. Some genetic syndromes can create a predisposition to leukemia, as well as other blood disorders.
Behind every marathon runner, there’s a story of personal inspiration. That’s definitely true for Katie Janeway, MD, a pediatric oncologist with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center who is also a cancer survivor.
It is most often worth it to seek a professional opinion, especially for a disease as complex as cancer.
“Amelia is an amazing and extremely bright girl who has faced her disease and treatment with tremendous courage,” says Steven DuBois, MD, MS, her oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.